翰森制药盘中最高价触及31.550港元，创近一年新高

Core Viewpoint - Hansoh Pharmaceutical is a leading innovation-driven pharmaceutical company in China, focusing on major disease treatments and achieving significant growth in revenue and innovative drug sales [2] Company Overview - Hansoh Pharmaceutical Group Limited is recognized for its commitment to continuous innovation aimed at improving human life quality, with a focus on oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases [2] - The company has established itself among the top 100 global pharmaceutical companies and is a key high-tech enterprise in China, having been listed on the Hong Kong Stock Exchange since June 2019 [2] Research and Development - Hansoh has set up four R&D centers in Shanghai, Lianyungang, Changzhou, and Maryland, USA, employing over 1,800 specialized R&D personnel [2] - The company has developed a comprehensive R&D system covering all stages from information gathering to clinical research, and has established several national-level research institutions [2] - Currently, there are 40 candidate innovative drug projects undergoing over 60 clinical trials, showcasing a competitive R&D pipeline [2] Financial Performance - In 2024, the company reported a revenue of 12.261 billion yuan, representing a year-on-year growth of 21.3%, with innovative drugs and cooperative product sales accounting for 9.477 billion yuan, or 77.3% of total revenue [2] - Seven innovative drugs have been approved for market launch, with nine indications included in the national medical insurance directory, significantly reducing patient medication costs [2] International Strategy - Hansoh is actively pursuing business development collaborations, having engaged in 11 introduced projects, with nine in clinical stages and two in commercialization [2] - The company has established licensing collaborations with leading international pharmaceutical firms such as GSK and Merck [2] Sustainability and Quality Standards - Hansoh integrates ESG principles into its long-term strategy, maintaining an MSCI ESG rating of AA and leading in key areas such as corporate governance and inclusive healthcare [2] - The company’s production quality system has received official certifications from the FDA, EMA, and PMDA, allowing its products to be sold in major international markets [2]